LYMPHOSEEK KIT Drug Patent Profile
✉ Email this page to a colleague
When do Lymphoseek Kit patents expire, and when can generic versions of Lymphoseek Kit launch?
Lymphoseek Kit is a drug marketed by Cardinal Health 414 and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in LYMPHOSEEK KIT is technetium tc-99m tilmanocept. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tilmanocept profile page.
DrugPatentWatch® Generic Entry Outlook for Lymphoseek Kit
Lymphoseek Kit was eligible for patent challenges on March 13, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 30, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
US Patents and Regulatory Information for LYMPHOSEEK KIT
LYMPHOSEEK KIT is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of LYMPHOSEEK KIT is ⤷ Start Trial.
This potential generic entry date is based on patent ⤷ Start Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LYMPHOSEEK KIT
When does loss-of-exclusivity occur for LYMPHOSEEK KIT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 10208624
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 1007487
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 50230
Patent: COMPOSITIONS DE RADIOMARQUAGE D'ACIDE DIETHYLENETRIAMINEPENTAACETIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Start Trial
China
Patent: 2301429
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 92012
Patent: COMPOSITIONS DE RADIOMARQUAGE D'ACIDE DIÉTHYLÈNETRIAMINEPENTAACÉTIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Start Trial
Patent: 84965
Patent: COMPOSITIONS DE RADIOMARQUAGE DE L'ACIDE DIÉTHYLÈNETRIAMINEPENTAACÉTIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 43905
Estimated Expiration: ⤷ Start Trial
Patent: 40276
Estimated Expiration: ⤷ Start Trial
Patent: 09796
Estimated Expiration: ⤷ Start Trial
Patent: 33892
Estimated Expiration: ⤷ Start Trial
Patent: 12516328
Patent: ジエチレントリアミン五酢酸（ＤＴＰＡ）−デキストランを放射標識するための組成物
Estimated Expiration: ⤷ Start Trial
Patent: 15164933
Patent: ジエチレントリアミン五酢酸（ＤＴＰＡ）−デキストランを放射標識するための組成物 (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Start Trial
Patent: 17066148
Patent: ジエチレントリアミン五酢酸（ＤＴＰＡ）−デキストランを放射標識するための組成物 (COMPOSITION FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Start Trial
Patent: 19178133
Patent: ジエチレントリアミン五酢酸（ＤＴＰＡ）−デキストランを放射標識するための組成物 (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINE PENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Start Trial
Patent: 21088566
Patent: ジエチレントリアミン五酢酸（ＤＴＰＡ）−デキストランを放射標識するための組成物 (COMPOSITIONS FOR RADIO-LABELLING DIETHYLENETRIAMINE PENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 1713559
Estimated Expiration: ⤷ Start Trial
Patent: 1765717
Estimated Expiration: ⤷ Start Trial
Patent: 110115148
Patent: 방사성 식별을 위한 디티피에이 덱스트란 조성물 (composition for radiolabeling diethylenetriaminepentaacetic acidDTPF-dextran)
Estimated Expiration: ⤷ Start Trial
Patent: 170027874
Patent: 방사성 식별을 위한 디티피에이 덱스트란 조성물 (composition for radiolabeling diethylenetriaminepentaacetic acidDTPF-dextran)
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering LYMPHOSEEK KIT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 277642 | ⤷ Start Trial | |
| Australia | 5270500 | ⤷ Start Trial | |
| Germany | 60014359 | ⤷ Start Trial | |
| European Patent Office | 1178838 | SUPPORT MACROMOLECULAIRE SUR BASE DE DEXTRAN POUR L'ADMINISTRATION D'UN AGENT DIAGNOSTIQUE OU THERAPEUTIQUE (MACROMOLECULAR CARRIER BASED ON DEXTRAN FOR DRUG AND DIAGNOSTIC AGENT DELIVERY) | ⤷ Start Trial |
| Spain | 2228536 | ⤷ Start Trial | |
| Japan | 2002544243 | ⤷ Start Trial | |
| Japan | 2007332380 | MACROMOLECULAR CARRIER FOR DELIVERY OF DRUG AND DIAGNOSTIC AGENT | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LYMPHOSEEK KIT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1178838 | 15C0033 | France | ⤷ Start Trial | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121 |
| 1178838 | 122015000033 | Germany | ⤷ Start Trial | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: C(2014) 8901 FINAL 20141119 |
| 1178838 | 300736 | Netherlands | ⤷ Start Trial | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
| 1178838 | 1590025-1 | Sweden | ⤷ Start Trial | PRODUCT NAME: TILMANOCEPT; REG. NO/DATE: EU/1/14/955 20141120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch